Achieve Life Sciences, Inc.

NASDAQ•ACHV

CEO: Mr. Thomas B. King M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 1995-10-12

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

連絡先情報

1040 West Georgia Street, Suite 1030, Vancouver, BC, V6E 4H1, Canada

604-210-2217

www.achievelifesciences.com

時価総額

$233.16M

PER (TTM)

-2.9

17.4

配当利回り

52週高値

$6.03

52週安値

$1.84

52週レンジ

61%

順位66Top 96.8%

1.5

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.5 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.28-22.22%

直近4四半期の推移

フリーCF

-$11.33M+9.25%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

NDA Accepted Smoking Cessation FDA accepted NDA for cytisinicline smoking cessation; PDUFA date set for June 20, 2026.

CNPV Awarded Vaping Cessation Received CNPV for vaping cessation indication in October 2025, expediting FDA review process.

Strong Financing Bolsters Cash Net cash provided by financing was $45.3M for nine months ended September 30, 2025.

Total Assets Increased Significantly Total assets grew to $52.04M as of September 30, 2025, up from $38.63M at year-end 2024.

リスク要因

Going Concern Uncertainty Exists Substantial doubt exists regarding ability to continue as going concern without substantial additional financing.

Increased Operating Loss Nine months ended September 30, 2025 net loss reached $40.0M, significantly higher than $27.5M loss prior year.

Sole Product Candidate Risk Business heavily dependent on cytisinicline success; regulatory approval or market acceptance is not guaranteed.

Third-Party Supply Dependence Commercialization relies on Sopharma supply agreement; disputes or failures could stop or delay product delivery.

見通し

US Commercialization Planning Plan to commence commercial sales of cytisinicline in the US market during the second half of 2026.

Require Substantial Future Capital Current resources insufficient to fund operations for next 12 months; substantial capital raise needed soon.

Pursue Vaping Cessation Indication Will pursue Phase 3 study design for vaping cessation indication following FDA guidance on sNDA submission.

Increased Operating Expenses Expected Expect operating expenses to increase substantially while continuing clinical development and preparing for commercial stage.

同業比較

売上高 (TTM)

VNDA

$216.11M

+8.7%

ARCT

$67.22M

-51.4%

VYGR

$40.37M

-49.5%

粗利益率 (最新四半期)

APLT

100.0%

+0.0pp

VNDA

93.3%

+0.1pp

VYGR

93.2%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CAPR	$1.53B	-18.7	-71.0%	11.5%
ALLO	$591.04M	-2.8	-57.8%	19.4%
VNDA	$549.11M	-2.5	-49.2%	2.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし